{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T12:22:30Z","timestamp":1773663750272,"version":"3.50.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:00:00Z","timestamp":1773619200000},"content-version":"vor","delay-in-days":34,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Urol"],"DOI":"10.1186\/s12894-026-02077-6","type":"journal-article","created":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T03:57:15Z","timestamp":1770695835000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of safety reporting in interventional trials of benign prostatic hyperplasia: a registry-publication comparison study"],"prefix":"10.1186","volume":"26","author":[{"given":"Malek","family":"Itani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanner","family":"Livsey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kellen","family":"Keefer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Elghzali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan","family":"Sherry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tag","family":"Harris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Archer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alicia Ito","family":"Ford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matt","family":"Vassar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,10]]},"reference":[{"key":"2077_CR1","unstructured":"UpToDate. https:\/\/www.uptodate.com\/contents\/surgical-treatment-of-benign-prostatic-hyperplasia-bph?search=benign%20prostatic%20hyperplasia&source=search_result&selectedTitle=3~132&usage_type=default&display_rank=3#H2024431412. Accessed July 3, 2025."},{"key":"2077_CR2","unstructured":"UpToDate. https:\/\/www.uptodate.com\/contents\/medical-treatment-of-benign-prostatic-hyperplasia?search=benign%20prostatic%20hyperplasia&source=search_result&selectedTitle=1~132&usage_type=default&display_rank=1. Accessed July 3, 2025."},{"key":"2077_CR3","unstructured":"ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/policy\/fdaaa-801-final-rule. Accessed July 3, 2025."},{"key":"2077_CR4","unstructured":"ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/. Accessed July 8, 2025."},{"key":"2077_CR5","unstructured":"Food and Drug Administration Amendments Act of. 2007. https:\/\/www.govinfo.gov\/content\/pkg\/PLAW-110publ85\/pdf\/PLAW-110publ85.pdf#page=82. Accessed July 25, 2025."},{"key":"2077_CR6","doi-asserted-by":"crossref","unstructured":"Wong EKC, Lachance CC, Page MJ, Watt J, Veroniki A, Straus SE, et al. Selective reporting bias in randomised controlled trials from two network meta-analyses: comparison of clinical trial registrations and their respective publications. BMJ Open. 2019;9(9):e031138.","DOI":"10.1136\/bmjopen-2019-031138"},{"key":"2077_CR7","doi-asserted-by":"crossref","unstructured":"Dibonaventura M, Gabriel S, Dupclay L, Gupta S, Kim E. A patient perspective of the impact of medication side effects on adherence: results of a cross-sectional nationwide survey of patients with schizophrenia. BMC Psychiatry. 2012;12(1):20.","DOI":"10.1186\/1471-244X-12-20"},{"key":"2077_CR8","unstructured":"PRISMA 2020 statement \u2014. PRISMA statement. https:\/\/www.prisma-statement.org\/prisma-2020. Accessed March 12, 2025."},{"key":"2077_CR9","unstructured":"The Strengthening the Reporting of Observational Studies in. Epidemiology (STROBE) Statement: guidelines for reporting observational studies. https:\/\/www.equator-network.org\/reporting-guidelines\/strobe\/. Accessed March 12, 2025."},{"key":"2077_CR10","doi-asserted-by":"publisher","unstructured":"Boyne N, Duke A, Rea J, Khan A, Young A, Van Vleet J, et al. Discrepancies in safety reporting for chronic back pain clinical trials: an observational study from ClinicalTrials.gov and publications. BMC Med Res Methodol. 2025. https:\/\/doi.org\/10.1186\/s12874-025-02486-5.","DOI":"10.1186\/s12874-025-02486-5"},{"key":"2077_CR11","doi-asserted-by":"publisher","unstructured":"Sivendran S, Latif A, McBride RB, Stensland KD, Wisnivesky J, Haines L, et al. Adverse event reporting in cancer clinical trial publications. J Clin Oncol. 2014. https:\/\/doi.org\/10.1200\/JCO.2013.52.2219.","DOI":"10.1200\/JCO.2013.52.2219"},{"key":"2077_CR12","unstructured":"PROSPERO. https:\/\/www.crd.york.ac.uk\/prospero\/. Accessed July 25, 2025."},{"key":"2077_CR13","unstructured":"Open Science Framework. https:\/\/osf.io\/. Accessed July 25, 2025."},{"key":"2077_CR14","unstructured":"45 CFR 46.102. -- Definitions for purposes of this policy. https:\/\/www.ecfr.gov\/current\/title-45\/subtitle-A\/subchapter-A\/part-46\/subpart-A\/section-46.102. Accessed July 3, 2025."},{"key":"2077_CR15","unstructured":"PROSPERO. https:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/CRD420251081216. Accessed July 10, 2025."},{"key":"2077_CR16","unstructured":"Hazlitt R, Corwin L, Archer D. Open Sci Framew Published 2025. Osf.io\/8q3yf."},{"key":"2077_CR17","unstructured":"Food and Drug Administration Amendments Act of 2007 (Pub L No. 110\u201385, 121 Stat 823; effective September 27, 2007). United States Government Publishing Office. Published September 27. 2007. https:\/\/www.govinfo.gov\/content\/pkg\/PLAW-110publ85\/pdf\/PLAW-110publ85.pdf#page=82. Accessed July 25, 2025."},{"key":"2077_CR18","unstructured":"42 CFR Part 11 -- Clinical Trials Registration and Results Information Submission. https:\/\/www.ecfr.gov\/current\/title-42\/chapter-I\/subchapter-A\/part-11. Accessed July 25, 2025."},{"key":"2077_CR19","unstructured":"Constructing Complex Search Queries. Clinicaltrials.gov. https:\/\/clinicaltrials.gov\/find-studies\/constructing-complex-search-queries#expansionOp. Accessed July 3, 2025."},{"key":"2077_CR20","doi-asserted-by":"publisher","unstructured":"Kre\u0161o A, Grahovac M, Znaor L, Maru\u0161i\u0107 A. Safety reporting in trials on glaucoma interventions registered in ClinicalTrials.gov and corresponding publications. Sci Rep. 2024. https:\/\/doi.org\/10.1038\/s41598-024-79394-z.","DOI":"10.1038\/s41598-024-79394-z"},{"key":"2077_CR21","unstructured":"Checklist for Evaluating Whether a Clinical Trial or Study is an Applicable Clinical Trial (ACT). Published online June 17. 2018. https:\/\/cdn.clinicaltrials.gov\/documents\/ACT_Checklist.pdf. Accessed July 1, 2025."},{"key":"2077_CR22","unstructured":"Elaboration of definitions. of responsible party and applicable clinical trial. https:\/\/cdn.clinicaltrials.gov\/documents\/ElaborationsOnDefinitions.pdf#:~:text=ELABORATION. Accessed July 22, 2025."},{"key":"2077_CR23","unstructured":"TITLE 21\u2014FOOD AND DRUGS. https:\/\/www.govinfo.gov\/content\/pkg\/USCODE-2023-title21\/pdf\/USCODE-2023-title21-chap9-subchapV-partE-sec360bbb.pdf. Accessed July 3, 2025."},{"key":"2077_CR24","doi-asserted-by":"publisher","first-page":"e073725","DOI":"10.1136\/bmj-2022-073725","volume":"381","author":"DR Junqueira","year":"2023","unstructured":"Junqueira DR, Zorzela L, Golder S, Loke Y, Gagnier JJ, Julious SA, et al. CONSORT harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomised trials. BMJ. 2023;381:e073725.","journal-title":"BMJ"},{"issue":"2","key":"2077_CR25","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","volume":"240","author":"D Dindo","year":"2004","unstructured":"Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205\u201313.","journal-title":"Ann Surg"},{"key":"2077_CR26","doi-asserted-by":"publisher","unstructured":"Penfold RB, Zhang F. Use of interrupted time series analysis in evaluating health care quality improvements. Acad Pediatr. 2013. https:\/\/doi.org\/10.1016\/j.acap.2013.08.002.","DOI":"10.1016\/j.acap.2013.08.002"},{"issue":"6","key":"2077_CR27","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1111\/jce.16682","volume":"36","author":"V Li\u0161ni\u0107","year":"2025","unstructured":"Li\u0161ni\u0107 V, \u0160aler F, Vi\u0111ak M, Maru\u0161i\u0107 A. Safety reporting in trials on atrial fibrillation: an observational study of ClinicalTrials.Gov registry and corresponding publications. J Cardiovasc Electrophysiol. 2025;36(6):1377\u201385.","journal-title":"J Cardiovasc Electrophysiol"},{"issue":"19","key":"2077_CR28","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1001\/archinternmed.2009.313","volume":"169","author":"JPA Ioannidis","year":"2009","unstructured":"Ioannidis JPA. Adverse events in randomized trials: neglected, restricted, distorted, and silenced. Arch Intern Med. 2009;169(19):1737\u20139.","journal-title":"Arch Intern Med"},{"issue":"11","key":"2077_CR29","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1056\/NEJMsa1409364","volume":"372","author":"ML Anderson","year":"2015","unstructured":"Anderson ML, Chiswell K, Peterson ED, Tasneem A, Topping J, Califf RM. Compliance with results reporting at ClinicalTrials.gov. N Engl J Med. 2015;372(11):1031\u20139.","journal-title":"N Engl J Med"},{"issue":"20","key":"2077_CR30","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1056\/NEJMsr1611785","volume":"375","author":"DA Zarin","year":"2016","unstructured":"Zarin DA, Tse T, Williams RJ, Carr S. Trial reporting in ClinicalTrials.Gov - the final rule. N Engl J Med. 2016;375(20):1998\u20132004.","journal-title":"N Engl J Med"},{"issue":"9","key":"2077_CR31","doi-asserted-by":"publisher","first-page":"e1000144","DOI":"10.1371\/journal.pmed.1000144","volume":"6","author":"JS Ross","year":"2009","unstructured":"Ross JS, Mulvey GK, Hines EM, Nissen SE, Krumholz HM. Trial publication after registration in ClinicalTrials.Gov: a cross-sectional analysis. PLoS Med. 2009;6(9):e1000144.","journal-title":"PLoS Med"},{"issue":"12","key":"2077_CR32","doi-asserted-by":"publisher","first-page":"e1001566","DOI":"10.1371\/journal.pmed.1001566","volume":"10","author":"C Riveros","year":"2013","unstructured":"Riveros C, Dechartres A, Perrodeau E, Haneef R, Boutron I, Ravaud P. Timing and completeness of trial results posted at ClinicalTrials.gov and published in journals. PLoS Med. 2013;10(12):e1001566. discussion e1001566.","journal-title":"PLoS Med"},{"key":"2077_CR33","unstructured":"Who\u2019s sharing their clinical trial results?. https:\/\/fdaaa.trialstracker.net\/. Accessed July 22, 2025."},{"issue":"2","key":"2077_CR34","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.prnil.2023.11.004","volume":"12","author":"A Halawani","year":"2024","unstructured":"Halawani A, Paterson R, Zhong T, Du K, Ren R, Forbes CM. Risks and side effects in the medical management of benign prostatic hyperplasia. Prostate Int. 2024;12(2):57\u201364.","journal-title":"Prostate Int"},{"key":"2077_CR35","doi-asserted-by":"crossref","unstructured":"Evidence-based medicine with UpToDate. https:\/\/www.wolterskluwer.com\/en\/solutions\/uptodate\/about\/evidence-based-medicine. Accessed July 22, 2025.","DOI":"10.1097\/01.EEM.0000000000000029"},{"key":"2077_CR36","unstructured":"Epocrates. https:\/\/www.epocrates.com\/about. Accessed July 22, 2025."},{"issue":"1","key":"2077_CR37","first-page":"19","volume":"28","author":"RW Halfond","year":"2021","unstructured":"Halfond RW, Wright CV, Bufka LF. The role of harms and burdens in clinical practice guidelines: lessons learned from the American psychological association\u2019s guideline development. Clin Psychol (New York). 2021;28(1):19\u201328.","journal-title":"Clin Psychol (New York)"}],"container-title":["BMC Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12894-026-02077-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-026-02077-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-026-02077-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T11:38:08Z","timestamp":1773661088000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12894-026-02077-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,10]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2077"],"URL":"https:\/\/doi.org\/10.1186\/s12894-026-02077-6","relation":{},"ISSN":["1471-2490"],"issn-type":[{"value":"1471-2490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,10]]},"assertion":[{"value":"22 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"IRB Status: Our research protocol was submitted to the Oklahoma State University Center for Health Sciences Institutional Review Board (IRB) (IRB # 2025078) for review and was determined to not meet the regulatory definition of human subject\u2019s research in accordance with the Code of Federal Regulations [45 CFR 46.102(d) and (f)].Adherence to the Declaration of Helsinki: Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not Applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"70"}}